• 1. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 2. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 3. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 4. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 5. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Aminopiperidines

Introduction to 1-methyl-N-(pentan-3-yl)piperidin-4-amine (CAS No. 1019580-79-0)

1-methyl-N-(pentan-3-yl)piperidin-4-amine, identified by its Chemical Abstracts Service (CAS) number 1019580-79-0, is a compound of significant interest in the field of pharmaceutical chemistry and drug discovery. This piperidine derivative exhibits a unique structural configuration that positions it as a potential candidate for various therapeutic applications. The compound’s molecular structure, featuring a methyl group at the 1-position and a pentan-3-yl side chain at the 4-position of the piperidine ring, contributes to its distinct pharmacological properties. These features make it a valuable scaffold for medicinal chemists exploring novel pharmacophores.

The synthesis and characterization of 1-methyl-N-(pentan-3-yl)piperidin-4-amine involve rigorous methodologies to ensure high purity and yield, which are critical for subsequent pharmacological evaluations. Advanced techniques such as NMR spectroscopy, mass spectrometry, and high-performance liquid chromatography (HPLC) are employed to confirm the compound’s identity and assess its chemical integrity. These analytical methods provide detailed insights into the molecular structure, helping researchers understand its potential interactions with biological targets.

In recent years, there has been growing interest in piperidine derivatives due to their versatility in drug design. The piperidine core is a common motif in many FDA-approved drugs, known for its ability to enhance binding affinity and metabolic stability. The introduction of alkyl chains, such as the pentan-3-yl group in this compound, can further modulate its pharmacokinetic properties, making it an attractive candidate for optimizing drug-like characteristics. This modification can influence solubility, permeability, and overall bioavailability, which are crucial factors in drug development.

Current research in medicinal chemistry highlights the importance of structural diversity in identifying new therapeutic agents. 1-methyl-N-(pentan-3-yl)piperidin-4-amine exemplifies how subtle structural modifications can lead to significant changes in biological activity. Studies have shown that piperidine derivatives can exhibit a range of pharmacological effects, including CNS activity, anti-inflammatory properties, and potential applications in treating neurological disorders. The specific arrangement of substituents in this compound may contribute to its unique profile, making it a promising candidate for further investigation.

The exploration of 1-methyl-N-(pentan-3-yl)piperidin-4-amine extends into the realm of computational chemistry and molecular modeling. These approaches allow researchers to predict how the compound might interact with biological targets at the molecular level. By simulating binding interactions with enzymes or receptors, scientists can gain insights into its potential mechanism of action. This computational screening helps prioritize compounds for experimental validation, streamlining the drug discovery process.

One of the most exciting aspects of working with 1-methyl-N-(pentan-3-yl)piperidin-4-amine is its potential in developing novel therapeutics. The compound’s structural features align well with current trends in drug design, where targeted modifications are made to improve efficacy and reduce side effects. For instance, studies have indicated that certain piperidine derivatives can act as modulators of neurotransmitter systems, offering possibilities for treating conditions such as depression or anxiety disorders. The presence of the pentan-3-yl group may enhance its ability to cross the blood-brain barrier, making it a viable candidate for central nervous system (CNS) drugs.

The synthesis strategies for 1-methyl-N-(pentan-3-yl)piperidin-4-am ine also reflect contemporary advancements in organic chemistry. Modern synthetic routes emphasize efficiency, sustainability, and scalability—key considerations for industrial applications. Techniques such as transition-metal-catalyzed reactions and asymmetric synthesis have been explored to optimize the production process. These methods not only improve yield but also minimize waste, aligning with green chemistry principles that are increasingly important in pharmaceutical manufacturing.

In conclusion,1-methyl-N-(pentan -3 -yl)piperidin -4 -amine (CAS No. 1019580 -79 -0) represents a fascinating subject of study in pharmaceutical chemistry. Its unique structural attributes and potential biological activities make it a compelling candidate for further research and development. As our understanding of drug design evolves,this compound will likely play a significant role in shaping future therapeutic strategies, particularly in areas where precise molecular interactions are critical.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)